Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Mantle-cell lymphoma (MCL) is a rather aggressive B-cell malignancy whose considerable variability of individual outcome is associated with clinical characteristics (Mantle Cell Lymphoma International Prognostic Index [MIPI]). The Ki-67 index is a strong independent prognostic factor; however, the biologic MIPI (MIPI-b) distinguishes only two groups, which does not appropriately depict the clinical heterogeneity. By using the cohort from the European MCL Younger and MCL Elderly trials, we aimed to evaluate the additional prognostic impact of cytology and growth pattern and to improve risk stratification with the Ki-67 index and MIPI.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): J. Clin. Oncol.

Title: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

ISSN (Electronic): 1527-7755

ISSN (Print): 0732-183X

Publication date (Electronic): Apr 20 2016

Volume: 34

Issue: 12

Affiliations

[1 ] Eva Hoster, Roswitha Forstpointner, Christian Schmidt, Wolfgang Hiddemann, Michael Unterhalt, and Martin H. Dreyling, University Hospital Munich; Eva Hoster, University of Munich, Munich; Andreas Rosenwald, University of Würzburg, Würzburg; Heinz-Wolfram Bernd, University Hospital Schleswig-Holstein, Lübeck; Sylvia Hartmann, University Hospital of Frankfurt, Frankfurt am Main; Christoph Loddenkemper, University Hospital Berlin Charité; Christoph Loddenkemper, Pathologie PathoTres, Berlin; Thomas F.E. Barth, University Medical Center Ulm; Stephan Stilgenbauer, University of Ulm, Ulm; Michael Hallek, Universität zu Köln, Köln; Ursula Vehling-Kaiser, Tagesklinik Hämatologie Onkologie, Landshut; Lothar Kanz, University of Tübingen, Tübingen; Michael Pfreundschuh, Universitätsklinik des Saarlandes, Homburg; Wolfram Klapper, University of Kiel, Kiel, Germany; Françoise Berger, LYSA Group; Nicole Brousse, Hopital Necker; Catherine Thieblemont, Hôpital Saint Louis; Olivier Hermine, University Paris Descartes; Olivier Hermine, Université Sorbonne Paris Cité, Paris; Bertrand Coiffier, Centre Hospitalier Lyon-Sud, Pierre-Bénite; Réda Bouabdallah, Service d'Hématologie, Marseille; Vincent Ribrag, Institut Gustave Roussy, Villejuif, France; Stefano Pileri, University of Bologna, Bologna, Italy; Grzegorz Rymkiewicz, The Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland; Roman Kodet, Charles University, Prague, Czech Republic; and Johanna C. Kluin-Nelemans, University of Groningen, Groningen, The Netherlands. eva.hoster@med.uni-muenchen.de.

[2 ] Eva Hoster, Roswitha Forstpointner, Christian Schmidt, Wolfgang Hiddemann, Michael Unterhalt, and Martin H. Dreyling, University Hospital Munich; Eva Hoster, University of Munich, Munich; Andreas Rosenwald, University of Würzburg, Würzburg; Heinz-Wolfram Bernd, University Hospital Schleswig-Holstein, Lübeck; Sylvia Hartmann, University Hospital of Frankfurt, Frankfurt am Main; Christoph Loddenkemper, University Hospital Berlin Charité; Christoph Loddenkemper, Pathologie PathoTres, Berlin; Thomas F.E. Barth, University Medical Center Ulm; Stephan Stilgenbauer, University of Ulm, Ulm; Michael Hallek, Universität zu Köln, Köln; Ursula Vehling-Kaiser, Tagesklinik Hämatologie Onkologie, Landshut; Lothar Kanz, University of Tübingen, Tübingen; Michael Pfreundschuh, Universitätsklinik des Saarlandes, Homburg; Wolfram Klapper, University of Kiel, Kiel, Germany; Françoise Berger, LYSA Group; Nicole Brousse, Hopital Necker; Catherine Thieblemont, Hôpital Saint Louis; Olivier Hermine, University Paris Descartes; Olivier Hermine, Université Sorbonne Paris Cité, Paris; Bertrand Coiffier, Centre Hospitalier Lyon-Sud, Pierre-Bénite; Réda Bouabdallah, Service d'Hématologie, Marseille; Vincent Ribrag, Institut Gustave Roussy, Villejuif, France; Stefano Pileri, University of Bologna, Bologna, Italy; Grzegorz Rymkiewicz, The Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland; Roman Kodet, Charles University, Prague, Czech Republic; and Johanna C. Kluin-Nelemans, University of Groningen, Groningen, The Netherlands.

Article

Publisher Item ID: JCO.2015.63.8387

DOI: 10.1200/JCO.2015.63.8387

PubMed ID: 26926679

SO-VID: b758f851-f8c5-4802-a527-91a0c0cc5c23

History

Data availability:

Comments

Comment on this article

scite_

Cited by 110

See all cited by